Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. 2003

Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
Department of Laboratory Medicine, Osaka University Graduate School of Medicine (D2), Yamada-oka 2-2, Osaka 565-0871, Suita, Japan. tanaka@labo.med.osaka-u.ac.jp

There is a hypothesis that autoimmune abnormalities in neurotransmitter receptors might cause some psychiatric disorders. Using a sensitive radioligand assay, we detected serum autoantibodies to recombinant human muscarinic cholinergic receptor 1 (CHRM1, 34.4%), mu-opioid receptor (OPRM1, 13.1%), 5-hydroxytryptamine receptor 1A (HTR1A, 7.4%), and dopamine receptor D2 (DRD2, 4.9%) in 122 psychiatric patients. Positive antibodies to CHRM1 were found in 34.1%, 34.9%, 33.3%, and 9.1% of patients with schizophrenic disorders (n=44), mood disorders (n=63), other psychiatric disorders (n=15) and autoimmune diseases (n=33), respectively. All three patients with neuroleptic maliganant syndrome had high activities of autoantibodies to CHRM1, OPRM1, and/or HTR1A. Our data suggest that autoimmunity to neurotransmitter receptors might be associated with the induction of psychiatric symptoms and have some relation to neuroleptic malignant syndrome.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009459 Neuroleptic Malignant Syndrome A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72) Neuroleptic-Induced Neuroleptic Malignant Syndrome,Neuroleptic-Malignant Syndrome, Neuroleptic Induced,NMS (Neuroleptic Malignant Syndrome),NMSs (Neuroleptic Malignant Syndrome),Neuroleptic Induced Neuroleptic Malignant Syndrome,Neuroleptic Malignant Syndrome, Neuroleptic Induced,Neuroleptic Malignant Syndromes,Syndrome, Neuroleptic Malignant,Syndromes, Neuroleptic Malignant
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000094942 Nociceptin Receptor A member of the opioid subfamily of the G PROTEIN-COUPLED RECEPTORS. It is the receptor for the endogenous neuropeptide nociceptin. It functions in modulating NOCICEPTION and the perception of pain. KOR-3 Protein,Kappa3-Related Opioid Receptor,MOR-C Protein,Nociceptin Receptors,OFQ Receptor,OFQ Receptors,ORL1 Receptor,ORL1 Receptors,Opiate Receptor-Like 1,Opioid Receptor-Like Protein,Opioid-Receptor-Like 1 Protein,Orphanin FQ Receptor,Orphanin FQ Receptors,Receptor, Nociceptin,Receptor, OFQ,Receptor, Orphanin FQ,Receptors, ORL1,Noci-R,1 Protein, Opioid-Receptor-Like,1, Opiate Receptor-Like,FQ Receptor, Orphanin,FQ Receptors, Orphanin,MOR C Protein,Noci R,Opioid Receptor Like 1 Protein,Protein, KOR-3,Protein, MOR-C,Protein, Opioid Receptor-Like,Protein, Opioid-Receptor-Like 1,Receptor, Kappa3-Related Opioid,Receptor-Like 1, Opiate,Receptor-Like Protein, Opioid,Receptors, Nociceptin,Receptors, Orphanin FQ

Related Publications

Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
September 2013, Frontiers in genetics,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
June 2011, Psychological medicine,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
January 2022, Metabolic brain disease,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
August 1988, Rinsho byori. The Japanese journal of clinical pathology,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
May 2006, Current neurovascular research,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
February 1982, Behavior genetics,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
December 2021, Science immunology,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
May 1981, Clinical genetics,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
September 1980, Life sciences,
Susumu Tanaka, and Hidenori Matsunaga, and Masahiro Kimura, and Ke ita Tatsumi, and Yoh Hidaka, and Toru Takano, and Takeshi Uema, and Masatoshi Takeda, and Nobuyuki Amino
May 2016, Neuropharmacology,
Copied contents to your clipboard!